Mevidalen is a selective positive allosteric modulator (PAM) of the dopamine D1 receptor subtype.
The scientists objective was to assess the safety and efficacy of mevidalen for treatment of cognition in patients with Lewy body dementia (LBD).
Mevidalen resulted in significant, dose-dependent improvements of MDS-UPDRS total score. The 30 mg and 75 mg mevidalen doses significantly improved ADCS-CGIC scores compared to placebo.
Increases in blood pressure, adverse events, and cardiovascular serious adverse events were most pronounced at the 75 mg dose.
Mevidalen harnesses a novel mechanism of action that improves motor symptoms associated with Lewy body dementia on top of standard of care while improving or not worsening non-motor symptoms associated with traditional dopaminergic therapy.